The DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.
Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?
Open accessAbstract
The majority of cancer patients assume concomitant medications for the treatment of cancer-related symptoms or co-morbidities. As immune checkpoint inhibitors expand in the treatment of a widening range of malignancies, drug-drug interactions have become an area of increasing interest due to the potential for some concomitant medications to exert immune-modulatory effects and influence outcomes from immunotherapy. Here, we review the evidence supporting this association across selected drug classes including antibiotics, proton pump inhibitors, metformin, and opioids.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, several factors, such as diet or concomitant drugs [8,9], were associated with changes in the gut microbiota composition and immune system functions, and their role in ICI efficacy modulation has yet to be fully elucidated.”
From A Clinical Outcome of the Anti-PD-1 Therapy of Melanoma in Polish Patients Is Mediated by Population-Specific Gut Microbiome Composition (2022) · cites this paper as [8]
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 6×
“In a previous study by our group,16 we showed that ATB therapy had a significantly detrimental impact on OS (2 vs 26 months, HR = 7.4; 95% CI: 4.2–12.9; p < .001) only if given within 30 d from ICI commencement, with no significant difference in OS seen in patients who received ATB concurrently with ICI.”
BackgroundInfluentialPD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291
Coutinho, A. E., & Chapman, K. E. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.04.005 · Cited by 1,815
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Das, S., & Johnson, D. B. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0805-8 · Cited by 1,145
Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis
Wheaton, W. W., Weinberg, S. E., Hamanaka, R. B., Soberanes, S., Sullivan, L. B., Anso, E., Glasauer, A., Dufour, E., Mutlu, G. M., Budigner, G. S., et al. (2014) · eLife · doi:10.7554/elife.02242 · Cited by 1,105 · cited 1×
“Metformin inhibits complex 1 of the mitochondrial electron transport chain, an essential metabolic source for cancer proliferation.(51) Via activation of the LKB1/AMPK pathway, metformin inhibits mTOR signaling and down-regulates proinflammatory pathways, making the tumor microenvironment less tolerogenic via downregu…”
BackgroundArbour, K. C., Mezquita, L., Long, N., Rizvi, H., Auclin, E., Ni, A., Martínez-Bernal, G., Ferrara, R., Lai, W. V., Hendriks, L. E. L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.0006 · Cited by 1,071 · cited 2×
“In one of the initial studies, Arbor et al.(25) looked at 640 patients with non-small cell lung cancer (NSCLC) and found that baseline use of steroids, defined as ≥10 mg prednisone equivalent, was associated with a reduced overall response rate (6% vs 19%; p = .”
ResultInfluentialAntibiotics and the Human Gut Microbiome: Dysbioses and Accumulation of Resistances
Francino, M. P. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.01543 · Cited by 945
Derosa, L., Hellmann, M. D., Spaziano, M., Halpenny, D., Fidelle, M., Rizvi, H., Long, N., Plodkowski, A. J., Arbour, K. C., Chaft, J. E., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy103 · Cited by 908
Cited by
Cortellini, A., Tucci, M., Adamo, V., Stucci, L. S., Russo, A., Tanda, E. T., Spagnolo, F., Rastelli, F., Bisonni, R., Santini, D., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001361 · Cited by 275
Self-citationCortellini, A., Maïo, M. D., Nigro, O., Leonetti, A., Cortinovis, D. L., Aerts, J. G. J. V., Guaitoli, G., Barbieri, F., Giusti, R., Ferrara, M. G., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002421 · Cited by 171
Self-citationButi, S., Bersanelli, M., Perrone, F., Tiseo, M., Tucci, M., Adamo, V., Stucci, L. S., Russo, A., Tanda, E. T., Spagnolo, F., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.09.033 · Cited by 127
Self-citationNASH and Hepatocellular Carcinoma: Immunology and Immunotherapy
Pinter, M., Pinato, D. J., Ramadori, P., & Heikenwalder, M. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1258 · Cited by 103
Self-citationCortellini, A., D’Alessio, A., Cleary, S., Buti, S., Bersanelli, M., Bordi, P., Tonini, G., Vincenzi, B., Tucci, M., Russo, A., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3116 · Cited by 87
Self-citation
Metadata
- Authors
- Hussain, N., Naeem, M., & Pinato, D. J.
- Affiliations
- Hammersmith Hospital (GB)
- Corresponding author
- Pinato, David J.
- Venue
- Human Vaccines & Immunotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2020-06-23
- Volume
- 17
- Issue
- 1
- Pages
- 55-61
- ISSN
- 2164-5515 (ISSN-L)
- 2164-554X
- PMC
- PMC7872020
- OpenAlex
- W3037219982
- Cited by
- 69
- References
- 64
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 6 · 2023: 12 · 2022: 23 · 2021: 7 · 2020: 4
- FWCI
- 1.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Human Vaccines & Immunotherapeutics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- NIHR Imperial Biomedical Research Centre (Push for Impact 2019)
- Wellcome Trust (PS3416)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- immune checkpoint inhibitors, concomitant medications, drug-drug interactions, immunotherapy, antibiotics, proton pump inhibitors, metformin, opioids, cancer immunotherapy outcomes
- MeSH terms
- Immune Checkpoint Inhibitors, Drug Interactions, Humans, Immunologic Factors, Immunotherapy, Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association? https://app.cochat.ai/papers/10.1080/21645515.2020.1769398
- The paper
- Hussain, N., Naeem, M., & Pinato, D. J. (2021). Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association? Human Vaccines & Immunotherapeutics. https://doi.org/10.1080/21645515.2020.1769398
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.